BridgeMD
Compares treatment options for Supraventricular Tachycardia
Official title NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular Tachycardia
ClinicalTrials.gov ID: NCT07617077
What this study is testing
- What it's testing
- Supraventricular tachycardia (SVT) is a common heart rhythm disorder seen in emergency departments, causing a rapid heartbeat (typically 150-250 beats per minute). The current best non-drug treatment, the modified Valsalva maneuver (mVM), successfully restores normal rhythm in about 43% of cases.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age 18 years or older
- Electrocardiographically confirmed supraventricular tachycardia (SVT): narrow QRS complex (≤120 ms), regular rhythm, rapid ventricular rate...
- Hemodynamic stability, defined as ALL of the following simultaneously present:
- Systolic blood pressure ≥90 mmHg
- Diastolic blood pressure ≥60 mmHg
You likely can't join if
- Age younger than 18 years
- Pregnancy (known or suspected)
- Inability to confirm SVT diagnosis by ECG criteria
- Delta wave or pre-excitation pattern on ECG (Wolff-Parkinson-White syndrome or asymptomatic pre-excitation) - due to risk of ventricular fibrillation...
- Wide QRS tachycardia (QRS ≥120 ms) where ventricular tachycardia cannot be excluded
- Absolute contraindication to modified Valsalva maneuver (inability to assume supine position or passive leg elevation)
See the full eligibility criteria
- Age 18 years or older
- Electrocardiographically confirmed supraventricular tachycardia (SVT): narrow QRS complex (≤120 ms), regular rhythm, rapid ventricular rate, documented on 12-lead ECG or continuous cardiac monitoring
- Hemodynamic stability, defined as ALL of the following simultaneously present:
- Systolic blood pressure ≥90 mmHg
- Diastolic blood pressure ≥60 mmHg
- Alert and oriented mental status (GCS 15)
- No signs of acute end-organ dysfunction
- Ability and willingness to provide written informed consent
- Age younger than 18 years
- Pregnancy (known or suspected)
- Inability to confirm SVT diagnosis by ECG criteria
- Delta wave or pre-excitation pattern on ECG (Wolff-Parkinson-White syndrome or asymptomatic pre-excitation) - due to risk of ventricular fibrillation with vagal maneuvers
- Wide QRS tachycardia (QRS ≥120 ms) where ventricular tachycardia cannot be excluded
- Absolute contraindication to modified Valsalva maneuver (inability to assume supine position or passive leg elevation)
- Contraindication to nasal swab (nasal surgery within 30 days, active epistaxis, visible nasal polyp or mass)
- Hemodynamic instability requiring immediate synchronized cardioversion
- Prior enrollment in this study (re-presentation with SVT)
- Refusal to participate
The study team makes the final eligibility decision.
Where it's taking place
- Istanbul, Pendik, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Istanbul, Pendik, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.